JP2017502997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502997A5 JP2017502997A5 JP2016546998A JP2016546998A JP2017502997A5 JP 2017502997 A5 JP2017502997 A5 JP 2017502997A5 JP 2016546998 A JP2016546998 A JP 2016546998A JP 2016546998 A JP2016546998 A JP 2016546998A JP 2017502997 A5 JP2017502997 A5 JP 2017502997A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- vesicle
- vesicles
- group
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 19
- -1 cationic lipid Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 239000012528 membrane Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000004055 small Interfering RNA Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- NYZTVPYNKWYMIW-WRBBJXAJSA-N 4-[[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-dimethylazaniumyl]methyl]benzoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)CC1=CC=C(C=C1)C([O-])=O)OC(=O)CCCCCCC\C=C/CCCCCCCC NYZTVPYNKWYMIW-WRBBJXAJSA-N 0.000 claims 3
- 239000000232 Lipid Bilayer Substances 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 108020005004 Guide RNA Proteins 0.000 claims 2
- 108010034143 Inflammasomes Proteins 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- BVKFQEAERCHBTG-UHFFFAOYSA-N 17,18,19-trihydroxypentatriacontane-16,20-dione Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCCCC BVKFQEAERCHBTG-UHFFFAOYSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 claims 1
- VGHMMKAOWFINON-UHFFFAOYSA-N 3-[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-methylamino]propanoic acid Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)OC(CN(CCC(=O)O)C)COC(CCCCCCCC=C/CCCCCCCC)=O VGHMMKAOWFINON-UHFFFAOYSA-N 0.000 claims 1
- 241000224489 Amoeba Species 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- JEFHZBOWUMVAQD-UHFFFAOYSA-N C(CCCCCCCC=C/CCCCCCCC)(=O)OC(CN(C)CC1=CC=C(C(=O)O)C=C1)COC(CCCCCCCC=C/CCCCCCCC)=O Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)OC(CN(C)CC1=CC=C(C(=O)O)C=C1)COC(CCCCCCCC=C/CCCCCCCC)=O JEFHZBOWUMVAQD-UHFFFAOYSA-N 0.000 claims 1
- COZACIHWINTJON-YEUCEMRASA-N CCCCCCCC/C=C\CCCCCCCC(OCC(C[N+](C)(C)CC(C)C([O-])=O)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O Chemical compound CCCCCCCC/C=C\CCCCCCCC(OCC(C[N+](C)(C)CC(C)C([O-])=O)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O COZACIHWINTJON-YEUCEMRASA-N 0.000 claims 1
- 108091079001 CRISPR RNA Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 125000005233 alkylalcohol group Chemical group 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 210000002583 cell-derived microparticle Anatomy 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 150000001985 dialkylglycerols Chemical class 0.000 claims 1
- UAKOZKUVZRMOFN-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CCCCCCCC\C=C/CCCCCCCC UAKOZKUVZRMOFN-JDVCJPALSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 244000053095 fungal pathogen Species 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 210000000224 granular leucocyte Anatomy 0.000 claims 1
- NRLNQCOGCKAESA-UHFFFAOYSA-N heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate Chemical compound CCCCCC=CCC=CCCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCCC=CCC=CCCCCC NRLNQCOGCKAESA-UHFFFAOYSA-N 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003622 mature neutrocyte Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000002082 metal nanoparticle Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims 1
- XVUQPECVOGMPRU-ZPPAUJSGSA-N n,n-dimethyl-1,2-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC XVUQPECVOGMPRU-ZPPAUJSGSA-N 0.000 claims 1
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims 1
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 claims 1
- 229940031182 nanoparticles iron oxide Drugs 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 239000002096 quantum dot Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929559P | 2014-01-21 | 2014-01-21 | |
| US61/929,559 | 2014-01-21 | ||
| PCT/IB2015/050436 WO2015110957A2 (en) | 2014-01-21 | 2015-01-20 | Hybridosomes, compositions comprising the same, processes for their production and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113819A Division JP7046872B2 (ja) | 2014-01-21 | 2019-06-19 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502997A JP2017502997A (ja) | 2017-01-26 |
| JP2017502997A5 true JP2017502997A5 (enExample) | 2017-12-21 |
| JP6598786B2 JP6598786B2 (ja) | 2019-10-30 |
Family
ID=52434912
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546998A Active JP6598786B2 (ja) | 2014-01-21 | 2015-01-20 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
| JP2019113819A Active JP7046872B2 (ja) | 2014-01-21 | 2019-06-19 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
| JP2022045805A Pending JP2022101548A (ja) | 2014-01-21 | 2022-03-22 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113819A Active JP7046872B2 (ja) | 2014-01-21 | 2019-06-19 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
| JP2022045805A Pending JP2022101548A (ja) | 2014-01-21 | 2022-03-22 | ハイブリドソーム、それを含む組成物、それらの製造方法、およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10561610B2 (enExample) |
| EP (2) | EP3791863B1 (enExample) |
| JP (3) | JP6598786B2 (enExample) |
| KR (3) | KR102396026B1 (enExample) |
| CN (2) | CN105934240B (enExample) |
| AU (3) | AU2015208837B2 (enExample) |
| CA (1) | CA2936514C (enExample) |
| DK (1) | DK3096741T3 (enExample) |
| EA (1) | EA037503B1 (enExample) |
| ES (1) | ES2821758T3 (enExample) |
| MX (2) | MX384911B (enExample) |
| WO (1) | WO2015110957A2 (enExample) |
| ZA (1) | ZA201604831B (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013070324A1 (en) | 2011-11-07 | 2013-05-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
| WO2014210448A1 (en) | 2013-06-27 | 2014-12-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
| EP3791863B1 (en) | 2014-01-21 | 2025-09-10 | Anjarium Biosciences AG | Process for the production of hybridosomes |
| US20170035700A1 (en) | 2014-04-11 | 2017-02-09 | University Of Louisville Research Foundation, Inc. | Coated edible plant-derived microvesicle compositions and methods for using the same |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| WO2017136430A1 (en) | 2016-02-01 | 2017-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CN107362370B (zh) * | 2016-05-13 | 2022-07-26 | 国家纳米科学中心 | 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法 |
| JP7088911B2 (ja) | 2016-05-18 | 2022-06-21 | モデルナティエックス インコーポレイテッド | リラキシンをコードするポリヌクレオチド |
| CN106280533B (zh) * | 2016-08-17 | 2018-03-09 | 赣南师范大学 | 一种近红外荧光染料及其合成方法和用于寄生虫荧光标记 |
| EP3292861A1 (en) * | 2016-09-13 | 2018-03-14 | Centre National De La Recherche Scientifique (Cnrs) | An in vitro method for obtaining a biohybrid vector |
| AU2018254263B2 (en) * | 2017-04-19 | 2022-07-14 | Apa- Advanced Technologies Ltd. | Fusogenic liposomes, compositions, kits and use thereof for treating cancer |
| CN107084956B (zh) * | 2017-05-05 | 2021-03-23 | 曲阜师范大学 | 一种基于醇溶剂诱导银纳米簇荧光增强的尿液中碘离子检测方法 |
| ES3052812T3 (en) * | 2017-05-08 | 2026-01-14 | Flagship Pioneering Innovations V Inc | Compositions for facilitating membrane fusion and uses thereof |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| EP3658125A4 (en) * | 2017-07-28 | 2021-04-28 | National University of Singapore | BIOMOLECULAR COMPOSITES INCLUDING MODIFIED CELL PHANTOMS |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| CN118389609A (zh) * | 2017-09-11 | 2024-07-26 | 加利福尼亚大学董事会 | 抗体介导的cas9向哺乳动物细胞的递送 |
| KR102008665B1 (ko) | 2017-09-30 | 2019-08-08 | 주식회사 엑소코바이오 | 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물 |
| WO2019066434A1 (ko) * | 2017-09-30 | 2019-04-04 | 주식회사 엑소코바이오 | 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물 |
| EP3710065B1 (en) * | 2017-11-13 | 2024-08-21 | Politecnico Di Torino | Biomimetic non-immunogenic nanoassembly for the antitumor therapy |
| US12036262B2 (en) | 2017-11-22 | 2024-07-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived nanoparticles for regulation of gut microbiota |
| CN108287134B (zh) * | 2017-12-28 | 2020-11-24 | 南京邮电大学 | 单颗粒生物探针及其等离子体生物存储器的构建方法 |
| SG11202007606QA (en) | 2018-02-17 | 2020-09-29 | Flagship Pioneering Innovations V Inc | Compositions and methods for membrane protein delivery |
| WO2019178317A1 (en) | 2018-03-14 | 2019-09-19 | Children's Medical Center Corporation | Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof |
| EP3773742A4 (en) | 2018-04-06 | 2022-03-16 | North Carolina State University | CELL SET-MEDIATED CHECKPOINT INHIBITOR DELIVERY FOR CANCER IMMUNOTHERAPY |
| JP2021521141A (ja) | 2018-04-09 | 2021-08-26 | オージェネシス インコーポレイテッド | バイオキソーム粒子、レドキソーム、それらの作製方法、及びそれらを含む組成物 |
| US20210236612A1 (en) * | 2018-04-26 | 2021-08-05 | University Of Louisville Research Foundation, Inc. | Edible plant exosome-like nanovectors for vaccination |
| CA3003032A1 (en) * | 2018-04-27 | 2019-10-27 | Nanostics Inc. | Methods of diagnosing disease using microflow cytometry |
| CN110437628B (zh) * | 2018-05-04 | 2021-05-04 | 中国石油化工股份有限公司 | 一种改性剂母液和道路沥青及其合成方法 |
| MX2020012295A (es) * | 2018-05-15 | 2021-03-31 | Flagship Pioneering Innovations V Inc | Composiciones de fusosoma y usos de estas. |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| US12109310B2 (en) | 2018-06-28 | 2024-10-08 | Hadi Valadi | Exosome extracellular vesicles and methods of use |
| WO2020014209A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| CA3117914A1 (en) * | 2018-10-24 | 2020-04-30 | Apa- Advanced Technologies Ltd. | Fusogenic liposomes for selective imaging of tumor cells |
| WO2020102485A1 (en) * | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| AU2019378036B2 (en) | 2018-11-14 | 2026-05-07 | Flagship Pioneering Innovations V, Inc | Compositions and methods for compartment-specific cargo delivery |
| CN109620969B (zh) * | 2019-01-30 | 2021-02-05 | 广东药科大学 | 一种针对耐药肿瘤细胞的靶向抗肿瘤药物体系及其构建方法 |
| WO2021010586A1 (ko) * | 2019-07-15 | 2021-01-21 | (주)심플스틱 | 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법 |
| EP4013740B1 (en) * | 2019-08-12 | 2026-04-08 | Integrated Nanotherapeutics Inc. | Lipids for delivery of charged material, formulations thereof and method for making same |
| WO2021034582A1 (en) * | 2019-08-16 | 2021-02-25 | Children's Medical Center Corporation | Large scale production of exosome mimetics and uses thereof |
| CN112415081A (zh) * | 2019-08-23 | 2021-02-26 | 四川大学 | 一种基于稳定同位素检测的无标记CRISPR-Cas9分析方法 |
| KR102297995B1 (ko) * | 2019-10-24 | 2021-09-02 | 포항공과대학교 산학협력단 | 개방 동공을 갖는 산화철 나노큐브, 이의 제조방법 및 이의 용도 |
| CN111007170B (zh) * | 2019-12-13 | 2021-06-29 | 中国农业科学院农产品加工研究所 | 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途 |
| CN116133652A (zh) * | 2020-01-31 | 2023-05-16 | 摩登纳特斯有限公司 | 制备脂质纳米粒子的方法 |
| EP3858332A1 (en) * | 2020-01-31 | 2021-08-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bottom-up assembly of synthetic extracellular vesicles |
| WO2021173840A1 (en) * | 2020-02-25 | 2021-09-02 | Translate Bio, Inc. | Improved processes of preparing mrna-loaded lipid nanoparticles |
| EP4121004A1 (en) * | 2020-03-20 | 2023-01-25 | University Of Heidelberg | Colloidal carrier systems for transfer of agents to a desired site of action |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| CN112094809A (zh) * | 2020-10-19 | 2020-12-18 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种从血清或血浆中提取外泌体的方法 |
| AU2022253020A1 (en) | 2021-04-08 | 2023-10-26 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
| WO2022219075A2 (en) | 2021-04-14 | 2022-10-20 | Anjarium Biosciences Ag | Peptides, nanovesicles, and uses thereof for drug delivery |
| AU2022259546A1 (en) | 2021-04-14 | 2023-11-16 | Anjarium Biosciences Ag | Fc-derived polypeptides |
| AU2022262350B2 (en) | 2021-04-20 | 2026-05-07 | Terrapower Isotopes, Llc | Titania based generators for ac-225 generation |
| WO2022255851A1 (ko) * | 2021-06-04 | 2022-12-08 | 기초과학연구원 | 나노소포체 반응기 및 이의 제조방법 |
| CA3226019A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| EP4393957A4 (en) * | 2021-08-23 | 2026-04-22 | Sekisui Chemical Co Ltd | Peptide-bound liposome-exosome hybrid, peptide-bound exosome, composition, container, and process for their formation |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| WO2023244084A1 (ko) * | 2022-06-17 | 2023-12-21 | 주식회사 엠디뮨 | 양이온성 지질 및 핵산분자를 포함하는 세포유래 베지클 및 이의 제조방법 |
| EP4608424A1 (en) | 2022-10-24 | 2025-09-03 | AGS Therapeutics SAS | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| WO2024170778A1 (en) | 2023-02-17 | 2024-08-22 | Anjarium Biosciences Ag | Methods of making dna molecules and compositions and uses thereof |
| US11944604B1 (en) | 2023-03-10 | 2024-04-02 | King Saud University | Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma |
| WO2024249782A2 (en) * | 2023-06-02 | 2024-12-05 | The Methodist Hospital | Biomimetic proteolipid nanovesicles for delivery of nucleic acids |
| EP4719632A1 (en) | 2023-07-06 | 2026-04-08 | National Resilience, LLC | Methods and compositions for purifying particles and macromolecules |
| KR20250018222A (ko) * | 2023-07-26 | 2025-02-05 | 차의과학대학교 산학협력단 | 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물 |
| WO2025100747A1 (ko) * | 2023-11-09 | 2025-05-15 | 주식회사 엑토좀 | 줄기세포 유래 엑토-리포좀 융합 나노입자 및 그의 용도 |
| WO2025137252A1 (en) * | 2023-12-20 | 2025-06-26 | Cz Biohub Sf, Llc | High throughput method for screening lipid nanoparticle efficacy and cytotoxicity |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
| WO2025196641A1 (ru) * | 2024-03-19 | 2025-09-25 | Биоплатформ Гмбх | Гибридные частицы, способ их получения и применение |
| KR20250150723A (ko) * | 2024-04-11 | 2025-10-21 | 주식회사 하이셀텍 | 하이브리드 엑소좀 및 이의 용도 |
| KR20250156281A (ko) * | 2024-04-25 | 2025-11-03 | 주식회사 보름바이오 | 고분자 나노입자와 세포막이 하이브리드화된 나노복합체 및 이의 의학적 용도 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552155A (en) * | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| WO2008092153A2 (en) * | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
| EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS |
| WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| EP2419144B1 (en) * | 2009-04-17 | 2019-08-07 | Oxford University Innovation Limited | Composition for delivery of genetic material |
| KR100950713B1 (ko) | 2009-07-15 | 2010-03-31 | (주)블루앤 | 음이온 발생기를 구비한 엘이디 램프 |
| WO2011022460A1 (en) | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Novel cationic lipids with various head groups for oligonucleotide delivery |
| WO2011043913A2 (en) | 2009-10-08 | 2011-04-14 | Merck Sharp & Dohme Corp. | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
| WO2011097480A1 (en) | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| JP5149921B2 (ja) * | 2010-02-19 | 2013-02-20 | 学校法人君が淵学園 | 癌細胞増殖抑制性ハイブリッド型リポソーム製剤 |
| HUE040658T2 (hu) | 2010-04-07 | 2019-03-28 | California Inst Of Techn | Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| CN102905728B (zh) | 2010-05-26 | 2015-11-25 | 西莱克塔生物科技公司 | 具有不偶合的佐剂的纳米载体组合物 |
| US8748667B2 (en) | 2010-06-04 | 2014-06-10 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| WO2012002760A2 (ko) * | 2010-07-01 | 2012-01-05 | 포항공과대학교 산학협력단 | 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법 |
| KR101130137B1 (ko) | 2010-07-02 | 2012-03-28 | 연세대학교 산학협력단 | 발광다이오드 모듈 |
| US20120058153A1 (en) | 2010-08-20 | 2012-03-08 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin |
| MX349088B (es) | 2010-09-20 | 2017-07-10 | Merck Sharp & Dohme | Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos. |
| KR20130114115A (ko) | 2010-09-30 | 2013-10-16 | 머크 샤프 앤드 돔 코포레이션 | 올리고뉴클레오티드 전달을 위한 저분자량 양이온성 지질 |
| CN103153347A (zh) | 2010-10-21 | 2013-06-12 | 默沙东公司 | 用于寡核苷酸递送的新型低分子量阳离子脂质 |
| WO2012061259A2 (en) | 2010-11-05 | 2012-05-10 | Merck Sharp & Dohme Corp. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
| WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
| WO2013048734A1 (en) * | 2011-09-28 | 2013-04-04 | Tufts Medical Center, Inc. | Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes |
| WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| JP2013128452A (ja) * | 2011-12-21 | 2013-07-04 | Toshiba Corp | 定量分析装置、定量分析方法、脂質膜小胞、及び試薬 |
| US9687448B2 (en) | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| US20160120818A1 (en) | 2013-02-07 | 2016-05-05 | Glaxosmithline Biological Sa | Pharmaceutical compositions comprising vesicles |
| EP3791863B1 (en) | 2014-01-21 | 2025-09-10 | Anjarium Biosciences AG | Process for the production of hybridosomes |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| WO2022219075A2 (en) | 2021-04-14 | 2022-10-20 | Anjarium Biosciences Ag | Peptides, nanovesicles, and uses thereof for drug delivery |
| AU2022259546A1 (en) | 2021-04-14 | 2023-11-16 | Anjarium Biosciences Ag | Fc-derived polypeptides |
| US20240358852A1 (en) | 2021-04-20 | 2024-10-31 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| JP2025504404A (ja) | 2022-01-14 | 2025-02-12 | アンジャリウム バイオサイエンシズ エージー | Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法 |
-
2015
- 2015-01-20 EP EP20190918.1A patent/EP3791863B1/en active Active
- 2015-01-20 KR KR1020167020767A patent/KR102396026B1/ko active Active
- 2015-01-20 MX MX2016009529A patent/MX384911B/es unknown
- 2015-01-20 EA EA201691448A patent/EA037503B1/ru unknown
- 2015-01-20 AU AU2015208837A patent/AU2015208837B2/en active Active
- 2015-01-20 KR KR1020227015021A patent/KR102507475B1/ko active Active
- 2015-01-20 DK DK15701846.6T patent/DK3096741T3/da active
- 2015-01-20 US US15/112,180 patent/US10561610B2/en active Active
- 2015-01-20 JP JP2016546998A patent/JP6598786B2/ja active Active
- 2015-01-20 WO PCT/IB2015/050436 patent/WO2015110957A2/en not_active Ceased
- 2015-01-20 ES ES15701846T patent/ES2821758T3/es active Active
- 2015-01-20 KR KR1020237007470A patent/KR102541164B1/ko active Active
- 2015-01-20 CN CN201580005079.XA patent/CN105934240B/zh active Active
- 2015-01-20 EP EP15701846.6A patent/EP3096741B1/en active Active
- 2015-01-20 CN CN202110078273.8A patent/CN112870163A/zh active Pending
- 2015-01-20 CA CA2936514A patent/CA2936514C/en active Active
-
2016
- 2016-07-13 ZA ZA2016/04831A patent/ZA201604831B/en unknown
- 2016-07-21 MX MX2021000174A patent/MX2021000174A/es unknown
-
2019
- 2019-06-19 JP JP2019113819A patent/JP7046872B2/ja active Active
-
2020
- 2020-01-02 US US16/732,567 patent/US11484500B2/en active Active
- 2020-09-07 AU AU2020227129A patent/AU2020227129B2/en active Active
-
2022
- 2022-03-22 JP JP2022045805A patent/JP2022101548A/ja active Pending
- 2022-08-19 AU AU2022218603A patent/AU2022218603B2/en active Active
- 2022-09-12 US US17/942,617 patent/US11944706B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019218349A5 (enExample) | ||
| CN102119217B (zh) | 用于核酸递送的新型制剂 | |
| US10653780B2 (en) | Amino lipids and methods for the delivery of nucleic acids | |
| EP2224912B1 (en) | Improved compositions and methods for the delivery of nucleic acids | |
| JP5977394B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| JP5464556B2 (ja) | 新規の正イオン性脂質、それの製造方法、およびそれを含む伝達体 | |
| US20120264810A1 (en) | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles | |
| JP6192061B2 (ja) | 中性脂質を含む両性リポソーム | |
| CN105916839B (zh) | 阳离子性脂质 | |
| JP2011507534A5 (enExample) | ||
| CA3123595A1 (en) | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same | |
| US20180245077A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
| US20180016583A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| JP2015525209A5 (enExample) | ||
| US20110313017A1 (en) | Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates | |
| Karmali et al. | Design, syntheses and in vitro gene delivery efficacies of novel mono-, di-and trilysinated cationic lipids: a structure− activity investigation | |
| JP6993359B2 (ja) | 生物学的活性物質の細胞への送達のための脂質および複合体 | |
| NL2033672B1 (en) | Compounds and compositions for delivery of agents to cells | |
| US20140178462A1 (en) | Amphoteric liposomes comprising neutral lipids | |
| JP7043411B2 (ja) | カチオン性脂質としての化合物 | |
| HK1160459B (en) | Improved amino lipids and methods for the delivery of nucleic acids |